☆ 4.6 Article

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Paul DiSilvestro et al.

Summary: Maintenance therapy with olaparib showed sustained progression-free survival benefit in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. After a 7-year follow-up, there was a clinically meaningful improvement in overall survival. The incidence of myelodysplastic syndrome and acute myeloid leukemia was low.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Genetics and anatomy sculpt immune-cell partners of ovarian cancer

Denarda Dangaj Laniti et al.

Summary: Therapeutic options for treating ovarian cancer need improvement, and data on the cellular, molecular, and mutational landscape during tumor growth and spread might aid in the development of new targeted therapies.

NATURE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Ovarian cancer mutational processes drive site-specific immune evasion

Ignacio Vazquez-Garcia et al.

Summary: This study provides insights into the relationship between mutational processes, anatomical sites, and immune resistance mechanisms in HGSOC, highlighting the importance of personalized immunotherapeutic approaches and early detection research.

NATURE (2022)

添加到收藏夹

Review Oncology

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Francoise Derouane et al.

Summary: Despite the increased use of neoadjuvant chemotherapy, there is a clinical need for predictive markers of response in breast cancer patients. In this review, we discuss the current knowledge about molecular biomarkers used for clinical decision making and the influence of intratumoral heterogeneity on their validation. Promising biomarkers, including pathological markers, genetic signatures, radiological techniques, and liquid biopsies, are described, along with their potential implementation in routine clinical practice.

CANCERS (2022)

添加到收藏夹

Article Obstetrics & Gynecology

Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)

Richard Penson et al.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

E. D. Capoluongo et al.

Summary: This study evaluated two academic genomic tests and a functional assay to detect homologous recombination deficiency (HRD) and compared the results with Myriad. The results demonstrated the feasibility of academic tests for assessing HRD status, showing robust concordance with Myriad and correlation with clinical outcome.

ESMO OPEN (2022)

添加到收藏夹

Meeting Abstract Oncology

OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA

Robert L. Coleman et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

添加到收藏夹

Article Oncology

FDAApproval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

Shaily Arora et al.

Summary: FDA approved olaparib monotherapy and combination therapy with bevacizumab for the first-line treatment of advanced ovarian cancer with BRCA mutations and homologous recombination deficient-positive status. Both treatments demonstrated clinically meaningful improvements in progression-free survival and favorable benefit-risk profiles in clinical trials.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Susana Banerjee et al.

Summary: The study demonstrated that maintenance therapy with olaparib for 2 years can extend progression-free survival to over 4.5 years in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. These results support the use of maintenance olaparib as a standard of care in this setting.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Obstetrics & Gynecology

Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

Ursula Matulonis et al.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1

William Bradley et al.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Current Ovarian Cancer Maintenance Strategies and Promising New Developments

Vinaya Gogineni et al.

Summary: While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years, highlighting the need for novel maintenance therapies. PARP inhibitors have gained approval in ovarian cancer maintenance, but their impact on overall survival is limited. This review focuses on current frontline ovarian cancer treatment and molecularly based approaches to ovarian cancer management.

JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Richard T. Penson et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

The forefront of ovarian cancer therapy: update on PARP inhibitors

M. R. Mirza et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

N. Colombo et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. Gonzalez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

I. Ray-Coquard et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Oncology

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

M. R. Mirza et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Safety and dose modification for patients receiving niraparib

J. S. Berek et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

K. Moore et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman et al.

LANCET (2017)

添加到收藏夹

Article Medicine, General & Internal

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

M. R. Mirza et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Oncology

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Geoffrey Kim et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Letter Oncology

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial

Andres M. Poveda et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Standardized Ki67 Diagnostics Using Automated Scoring-Clinical Validation in the GeparTrio Breast Cancer Study

Frederick Klauschen et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Communication

Health Literacy and Health-Related Quality of Life Among a Population-Based Sample of Cancer Patients

Julie L. Halverson et al.

JOURNAL OF HEALTH COMMUNICATION (2015)

添加到收藏夹

Article Immunology

Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study

Mel C. Heeran et al.

APMIS (2013)

添加到收藏夹

Article Cell Biology

Human Papillomavirus Infection and Its Possible Correlation with p63 Expression in Cervical Cancer in Japan, Mongolia, and Myanmar

Ulziibat Shirendeb et al.

ACTA HISTOCHEMICA ET CYTOCHEMICA (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species

Bart Hooghe et al.

NUCLEIC ACIDS RESEARCH (2008)

添加到收藏夹

Article Obstetrics & Gynecology

Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining

K Kritpracha et al.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.